Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The therapy uses a patient's own immune cells, modified to target a protein (B7-H3) on cancer cells. The main goals are to ch…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Apr 28, 2026 13:10 UTC